EUVIMEDEUVIMED entdecken
Open Access

Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma

Alexandria Li, Deborah Sultan, Gyu Seong Heo, Lisa Detering, Divangana Lahad, Hannah Luehmann, Xiaohui Zhang, Rajiu Venkatesan, Jennifer Frye, Julie Belmar, Salma Ramadan, Robert Crowder und 11 weitere

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.271601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Alexandria Li und 22 weiteren Autor:innen. Beteiligte Einrichtung: Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri. Hauptthemen laut MEDLINE: Receptors, CCR2, Biomarkers, Tumor, Positron-Emission Tomography, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Because of the lack of prognostic biomarkers, most patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed at an advanced stage of the disease, leading to poor overall survival. There is an unmet need to identify biomarkers for the assessment of HNSCC. The goal of this study was to assess C-C chemokine receptor type 2 (CCR2) as a new diagnostic biomarker for HNSCC.

Methods

The sensitivity and specificity of the CCR2-targeting radiotracer 64Cu-DOTA-ECL1i for tumor detection was assessed in a mouse oral carcinoma 1 (MOC1) xenograft model and compared with 18F-FDG. The capability of 64Cu-DOTA-ECL1i for monitoring MOC1 tumor treatment response was evaluated for multiple treatment strategies. The CCR2 inhibitor propagermanium was used for targeted therapy in the MOC1 tumor model, followed by 64Cu-DOTA-ECL1i imaging. The translational potential of 64Cu-DOTA-ECL1i for HNSCC imaging was further investigated using patient-derived xenograft models. Proof-of-concept studies were performed using primary tumors and lymph node metastases of 11 patients with HNSCC. Histopathologic analyses of tumors in mice and humans were performed to characterize the expression of CCR2 and associated cell types.

Results

64Cu-DOTA-ECL1i PET imaged MOC1 tumors with high contrast, tracked the increase of tumor volume, and monitored the treatment responses. Propagermanium effectively inhibited MOC1 tumor growth and significantly improved survival. In the patient-derived xenograft model, 64Cu-DOTA-ECL1i accurately identified the tumors and sensitively tracked their progression. In patients with HNSCC, CCR2 PET revealed strong and heterogeneous uptake within primary tumors and metastatic lymph nodes. Tissue analyses demonstrated overexpression of CCR2 on both tumor cells and macrophages.

Conclusion

64Cu-DOTA-ECL1i PET accurately detected the expression of CCR2 in patients with HNSCC. The effectiveness of propagermanium in the inhibition of MOC1 tumor progression indicated its potential for HNSCC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Biomarkers, TumorPositron-Emission TomographySquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAnimalsMiceHumansCell Line, TumorFemaleCopper RadioisotopesGermaniumOrganometallic CompoundsPropionates

Stichwörter der Autor:innen

CCR2HNSCCbiomarkermacrophagepropagermaniumtumor

Substanzen

Receptors, CCR2Biomarkers, TumorCopper RadioisotopespropagermaniumCCR2 protein, humanGermaniumOrganometallic CompoundsPropionates

Autor:innen und Institutionen

  • Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri.
  • Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
  • Department of Medicine, Washington University in St. Louis, St Louis, Missouri.
  • Department of Otolaryngology, Washington University in St. Louis, St. Louis, Missouri.
  • Department of Medicine, University of Missouri, Columbia; Missouri.
  • Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri; and.

Förderung

  • NIBIB NIH HHS
  • NIH HHS

Zitieren

APA

Li, A., Sultan, D., Heo, G. S., Detering, L., Lahad, D., Luehmann, H., Zhang, X., Venkatesan, R., Frye, J., Belmar, J., Ramadan, S., Crowder, R., Nai, Y. H., Tao, J., Gropler, R., Laforest, R., Jackson, R. S., Chernock, R., Lin, C. Y., …, & Liu, Y. (2026). Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271601

Vancouver

Li A, Sultan D, Heo GS, Detering L, Lahad D, Luehmann H, et al. Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271601

BibTeX
@article{Li2026,
  author = {Li, Alexandria and Sultan, Deborah and Heo, Gyu Seong and Detering, Lisa and Lahad, Divangana and Luehmann, Hannah and Zhang, Xiaohui and Venkatesan, Rajiu and Frye, Jennifer and Belmar, Julie and Ramadan, Salma and Crowder, Robert and Nai, Ying-Hwey and Tao, Joan and Gropler, Robert and Laforest, Richard and Jackson, Ryan S and Chernock, Rebecca and Lin, Chieh-Yu and Li, Shunqiang and Puram, Sidharth and Dehdashti, Farrokh and Liu, Yongjian},
  title = {Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.271601}
}
Kostenlos starten →